Table 1.
Baseline characteristics.
| Empagliflozin 10 mg daily (n = 33) | Placebo (n = 33) | |
|---|---|---|
| Age (years) | 61.6 (8.7) | 64.6 (9.5) |
| Male | 30 (90.9) | 33 (100) |
| Duration of type 2 diabetes (years) | 11.9 (9.4) | 10.1 (7.2) |
| HbA1c (%) | 7.9 (0.9) | 7.9 (0.9) |
| BMI (kg/m2) | 28.2 (4.9) | 26.8 (4.6) |
| Office-based systolic BP (mmHg) | 139.2 (23.0) | 136.4 (21.4) |
| Office-based diastolic BP (mmHg) | 79.6 (12.4) | 75.1 (11.1) |
| eGFR (mL/min/1.73m2) | 90.2 (16.3) | 86.6 (17.4) |
| Hypertension | 29 (87.9) | 29 (87.9) |
| Hypercholesterolemia | 24 (72.7) | 26 (78.8) |
| Stroke or TIA | 7 (21.2) | 4 (12.1) |
| Peripheral artery disease | 2 (6.1) | 2 (6.1) |
| History of heart failure | 1 (3.0) | 4 (12.1) |
| History of smoking | 13 (39.4) | 15 (45.5) |
| ACEi/ARB | 29 (87.9) | 29 (87.9) |
| Beta-blocker | 27 (81.8) | 29 (87.9) |
| Calcium channel blocker | 5 (15.2) | 8 (24.2) |
Categorical data are presented as n (%); continuous variables are reported as mean (SD).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; TIA, transient ischemic attack.